NCT03452878 · ACTIVE NOT RECRUITING
Evaluation of the Functional Results of Bilateral Amygdalotomy for Refractory Aggressive Patients
This trial is studying bilateral amygdalotomy — a surgical procedure that destroys a small part of the amygdala, a brain structure linked to aggression — in patients whose severe aggression has not responded to medication. Researchers will use brain imaging, clinical assessments, and hormone levels to evaluate outcomes. The phase is unspecified, and details on long-term safety and efficacy are limited.
You may qualify if
- Refractory aggression (Adler et al., 2015) defined by extreme levels of aggression after the use of Risperidone or Aripiprazole ou combination of others psychoactive drugs.
You're excluded if
- Patients with anatomical alterations that may disrupt the surgery, infections or non-controlled diseases, treatment with other experimental drugs, pregnant women or during lactation, psychological or sociological conditions that will not permit the patient to be accompanied by the medical staff.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-10-08